Login / Signup

Factor XIa Inhibitors as New Anticoagulants.

Mimi L QuanDonald J P PintoJoanne M SmallheerWilliam R EwingKaren A RossiJoseph M LuettgenDietmar A SeiffertRuth R Wexler
Published in: Journal of medicinal chemistry (2018)
With the introduction of thrombin and factor Xa inhibitors to the oral anticoagulant market, significant improvements in both efficacy and safety have been achieved. Early clinical and preclinical data suggest that inhibitors of factor XIa can provide a still safer alternative, with expanded efficacy for arterial indications. This Perspective provides an overview of target rationale and details of the discovery and development of inhibitors of factor XIa as next generation antithrombotic agents.
Keyphrases
  • atrial fibrillation
  • small molecule
  • clinical trial
  • stem cells
  • venous thromboembolism
  • electronic health record
  • high throughput
  • cell therapy
  • machine learning
  • mesenchymal stem cells
  • bone marrow
  • deep learning